BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35200077)

  • 1. Tumour treating fields in glioblastoma: is the treatment tolerable, effective, and practical in UK patients?
    Olubajo F; Thorpe A; Davis C; Sinha R; Crofton A; Mills SJ; Williams M; Jenkinson MD; Price SJ; Watts C; Brodbelt AR
    Br J Neurosurg; 2022 Dec; 36(6):770-776. PubMed ID: 35200077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.
    Stupp R; Wong ET; Kanner AA; Steinberg D; Engelhard H; Heidecke V; Kirson ED; Taillibert S; Liebermann F; Dbalý V; Ram Z; Villano JL; Rainov N; Weinberg U; Schiff D; Kunschner L; Raizer J; Honnorat J; Sloan A; Malkin M; Landolfi JC; Payer F; Mehdorn M; Weil RJ; Pannullo SC; Westphal M; Smrcka M; Chin L; Kostron H; Hofer S; Bruce J; Cosgrove R; Paleologous N; Palti Y; Gutin PH
    Eur J Cancer; 2012 Sep; 48(14):2192-202. PubMed ID: 22608262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives.
    Zhu P; Zhu JJ
    Chin Clin Oncol; 2017 Aug; 6(4):41. PubMed ID: 28841803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of tumor treating fields for newly diagnosed glioblastoma: understanding of nationwide practice patterns.
    McClelland S; Sosanya O; Mitin T; Degnin C; Chen Y; Attia A; Suh JH; Jaboin JJ
    J Neurooncol; 2018 Oct; 140(1):155-158. PubMed ID: 29987746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of tumour-treating fields (TTFields) therapy for newly diagnosed glioblastoma in Japanese patients using the Novo-TTF System: a prospective post-approval study.
    Nishikawa R; Yamasaki F; Arakawa Y; Muragaki Y; Narita Y; Tanaka S; Yamaguchi S; Mukasa A; Kanamori M
    Jpn J Clin Oncol; 2023 Apr; 53(5):371-377. PubMed ID: 36647599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternating electric tumor treating fields for treatment of glioblastoma: rationale, preclinical, and clinical studies.
    Mittal S; Klinger NV; Michelhaugh SK; Barger GR; Pannullo SC; Juhász C
    J Neurosurg; 2018 Feb; 128(2):414-421. PubMed ID: 28298023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour Treating Fields (TTFs) for recurrent and newly diagnosed glioblastoma multiforme.
    Mirza FA; Shamim MS
    J Pak Med Assoc; 2018 Oct; 68(10):1543-1545. PubMed ID: 30317361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Treating Fields Utilization in a Glioblastoma Patient with a Preexisting Cardiac Pacemaker: The First Reported Case.
    McClelland S; Henrikson CA; Ciporen JN; Jaboin JJ; Mitin T
    World Neurosurg; 2018 Nov; 119():58-60. PubMed ID: 30064027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme.
    Gainer JL; Sheehan JP; Larner JM; Jones DR
    J Neurosurg; 2017 Feb; 126(2):460-466. PubMed ID: 27177177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
    Taphoorn MJB; Dirven L; Kanner AA; Lavy-Shahaf G; Weinberg U; Taillibert S; Toms SA; Honnorat J; Chen TC; Sroubek J; David C; Idbaih A; Easaw JC; Kim CY; Bruna J; Hottinger AF; Kew Y; Roth P; Desai R; Villano JL; Kirson ED; Ram Z; Stupp R
    JAMA Oncol; 2018 Apr; 4(4):495-504. PubMed ID: 29392280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of tumor-treating fields in recurrent glioblastoma: a systematic review and meta-analysis.
    Li X; Jia Z; Yan Y
    Acta Neurochir (Wien); 2022 Aug; 164(8):1985-1993. PubMed ID: 35397674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case of glioblastoma patient treated with tumor treating fields therapy at recurrence degenerating to sarcoma.
    Majd P; O'Connell DE; Kim RC; Bota DA; Carrillo JA
    CNS Oncol; 2017 Apr; 6(2):89-94. PubMed ID: 28303729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review of tumor treating fields therapy for high-grade gliomas.
    Shah PP; White T; Khalafallah AM; Romo CG; Price C; Mukherjee D
    J Neurooncol; 2020 Jul; 148(3):433-443. PubMed ID: 32578135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour Treating Fields (TTFs) for Paediatric Brain Tumours, Brain Metastases and other Novel Applications.
    Mirza FA; Shamim MS
    J Pak Med Assoc; 2018 Nov; 68(11):1729-1731. PubMed ID: 30410163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Treating Fields in Neuro-Oncological Practice.
    Mrugala MM; Ruzevick J; Zlomanczuk P; Lukas RV
    Curr Oncol Rep; 2017 Aug; 19(8):53. PubMed ID: 28664468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
    Zhu JJ; Demireva P; Kanner AA; Pannullo S; Mehdorn M; Avgeropoulos N; Salmaggi A; Silvani A; Goldlust S; David C; Benouaich-Amiel A;
    J Neurooncol; 2017 Dec; 135(3):545-552. PubMed ID: 28849310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
    Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study.
    Costa BM; Caeiro C; Guimarães I; Martinho O; Jaraquemada T; Augusto I; Castro L; Osório L; Linhares P; Honavar M; Resende M; Braga F; Silva A; Pardal F; Amorim J; Nabiço R; Almeida R; Alegria C; Pires M; Pinheiro C; Carvalho E; Lopes JM; Costa P; Damasceno M; Reis RM
    Oncol Rep; 2010 Jun; 23(6):1655-62. PubMed ID: 20428822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor treating field therapy in combination with bevacizumab for the treatment of recurrent glioblastoma.
    Omar AI
    J Vis Exp; 2014 Oct; (92):e51638. PubMed ID: 25407354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis.
    Marenco-Hillembrand L; Wijesekera O; Suarez-Meade P; Mampre D; Jackson C; Peterson J; Trifiletti D; Hammack J; Ortiz K; Lesser E; Spiegel M; Prevatt C; Hawayek M; Quinones-Hinojosa A; Chaichana KL
    J Neurooncol; 2020 Apr; 147(2):297-307. PubMed ID: 32157552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.